ID   ENOA_HUMAN              Reviewed;         434 AA.
AC   P06733; B2RD59; P22712; Q16704; Q4TUS4; Q53FT9; Q53HR3; Q658M5; Q6GMP2;
AC   Q71V37; Q7Z3V6; Q8WU71; Q96GV1; Q9BT62; Q9UCH6; Q9UM55;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   28-JAN-2026, entry version 270.
DE   RecName: Full=Alpha-enolase {ECO:0000303|PubMed:2373081};
DE            EC=4.2.1.11 {ECO:0000269|PubMed:1369209, ECO:0000269|PubMed:29775581};
DE   AltName: Full=2-phospho-D-glycerate hydro-lyase;
DE   AltName: Full=C-myc promoter-binding protein {ECO:0000303|PubMed:2005901};
DE   AltName: Full=Enolase 1;
DE   AltName: Full=MBP-1;
DE   AltName: Full=MPB-1;
DE   AltName: Full=Non-neural enolase;
DE            Short=NNE;
DE   AltName: Full=Phosphopyruvate hydratase;
DE   AltName: Full=Plasminogen-binding protein;
GN   Name=ENO1 {ECO:0000312|HGNC:HGNC:3350}; Synonyms=ENO1L1, MBPB1, MPB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-ENOLASE).
RX   PubMed=3529090; DOI=10.1073/pnas.83.18.6741;
RA   Giallongo A., Feo S., Moore R., Croce C.M., Showe L.C.;
RT   "Molecular cloning and nucleotide sequence of a full-length cDNA for human
RT   alpha enolase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6741-6745(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=T-cell;
RX   PubMed=2373081; DOI=10.1111/j.1432-1033.1990.tb15611.x;
RA   Giallongo A., Oliva D., Cali L., Barba G., Barbieri G., Feo S.;
RT   "Structure of the human gene for alpha-enolase.";
RL   Eur. J. Biochem. 190:567-573(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MBP-1), AND FUNCTION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=2005901; DOI=10.1128/mcb.11.4.2154-2161.1991;
RA   Ray R., Miller D.M.;
RT   "Cloning and characterization of a human c-myc promoter-binding protein.";
RL   Mol. Cell. Biol. 11:2154-2161(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-ENOLASE), AND MARKER FOR
RP   ENDOMETRIOSIS.
RC   TISSUE=Endometrium;
RX   PubMed=8824716; DOI=10.1016/s0896-8411(95)80027-1;
RA   Walter M., Berg H., Leidenberger F.A., Schweppe K.W., Northemann W.;
RT   "Autoreactive epitopes within the human alpha-enolase and their recognition
RT   by sera from patients with endometriosis.";
RL   J. Autoimmun. 8:931-945(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Adipose tissue, and Kidney proximal tubule;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Retina, and Stomach;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-177.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Brain, Eye, Lung, Ovary, Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-9 (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-28; 65-80; 121-162; 234-253; 270-281; 331-394 AND
RP   407-420, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Lilla S., Zebisch A., Kolch W.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 16-28; 33-50; 93-103; 106-120; 163-179; 184-193;
RP   203-221; 240-253; 257-262; 270-281; 286-326; 336-394 AND 407-412, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 166-434.
RX   PubMed=9653645; DOI=10.1006/geno.1997.5186;
RA   Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.;
RT   "Molecular cloning and expression analysis of five novel genes in
RT   chromosome 1p36.";
RL   Genomics 50:187-198(1998).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 171-434.
RC   TISSUE=Brain;
RX   PubMed=9110174; DOI=10.1101/gr.7.4.353;
RA   Yu W., Andersson B., Worley K.C., Muzny D.M., Ding Y., Liu W.,
RA   Ricafrente J.Y., Wentland M.A., Lennon G., Gibbs R.A.;
RT   "Large-scale concatenation cDNA sequencing.";
RL   Genome Res. 7:353-358(1997).
RN   [18]
RP   PROTEIN SEQUENCE OF 203-228, FUNCTION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND PATHWAY.
RC   TISSUE=Lymphoma;
RX   PubMed=1369209; DOI=10.1007/bf00570890;
RA   Sugahara T., Nakajima H., Shirahata S., Murakami H.;
RT   "Purification and characterization of immunoglobulin production stimulating
RT   factor-II beta derived from Namalwa cells.";
RL   Cytotechnology 10:137-146(1992).
RN   [19]
RP   PROTEIN SEQUENCE OF 270-281 AND 307-321, AND INDUCTION IN DIFFUSE LARGE
RP   CELL LYMPHOMA.
RX   PubMed=7787969; DOI=10.1159/000474967;
RA   Mohamad R.M., Hamdan M.Y., Maki A., Al-Katib A.;
RT   "Induced expression of alpha-enolase in differentiated diffuse large cell
RT   lymphoma.";
RL   Enzyme Protein 48:37-44(1994).
RN   [20]
RP   FUNCTION OF MBP1, IDENTIFICATION OF REPRESSOR DOMAINS, AND MUTAGENESIS OF
RP   LEU-384 AND LEU-388.
RX   PubMed=10082554; DOI=10.1128/mcb.19.4.2880;
RA   Ghosh A.K., Steele R., Ray R.B.;
RT   "Functional domains of c-myc promoter binding protein 1 involved in
RT   transcriptional repression and cell growth regulation.";
RL   Mol. Cell. Biol. 19:2880-2886(1999).
RN   [21]
RP   FUNCTION AS A C-MYC TRANSCRIPTIONAL REPRESSOR, AND SUBCELLULAR LOCATION.
RX   PubMed=10802057; DOI=10.1016/s0014-5793(00)01494-0;
RA   Feo S., Arcuri D., Piddini E., Passantino R., Giallongo A.;
RT   "ENO1 gene product binds to the c-myc promoter and acts as a
RT   transcriptional repressor: relationship with Myc promoter-binding protein 1
RT   (MBP-1).";
RL   FEBS Lett. 473:47-52(2000).
RN   [22]
RP   FUNCTION IN PLASMINOGEN ACTIVATION.
RX   PubMed=12666133; DOI=10.1002/ajh.10299;
RA   Lopez-Alemany R., Longstaff C., Hawley S., Mirshahi M., Fabregas P.,
RA   Jardi M., Merton E., Miles L.A., Felez J.;
RT   "Inhibition of cell surface mediated plasminogen activation by a monoclonal
RT   antibody against alpha-enolase.";
RL   Am. J. Hematol. 72:234-242(2003).
RN   [23]
RP   INTERACTION WITH PLG.
RX   PubMed=9308760;
RA   Arza B., Felez J., Lopez-Alemany R., Miles L.A., Munoz-Canoves P.;
RT   "Identification of an epitope of alpha-enolase (a candidate plasminogen
RT   receptor) by phage display.";
RL   Thromb. Haemost. 78:1097-1103(1997).
RN   [24]
RP   EPITOPE MAPPING, AND ASSOCIATION WITH CAR.
RX   PubMed=9878089; DOI=10.1006/jaut.1998.0239;
RA   Adamus G., Amundson D., Seigel G.M., Machnicki M.;
RT   "Anti-enolase-alpha autoantibodies in cancer-associated retinopathy:
RT   epitope mapping and cytotoxicity on retinal cells.";
RL   J. Autoimmun. 11:671-677(1998).
RN   [25]
RP   IDENTIFICATION OF MBP1 AS AN ALPHA-ENOLASE ALTERNATIVE INITIATION PRODUCT,
RP   AND MUTAGENESIS OF MET-94 AND MET-97.
RX   PubMed=10681589; DOI=10.1074/jbc.275.8.5958;
RA   Subramanian A., Miller D.M.;
RT   "Structural analysis of alpha-enolase. Mapping the functional domains
RT   involved in down-regulation of the c-myc protooncogene.";
RL   J. Biol. Chem. 275:5958-5965(2000).
RN   [26]
RP   REVIEW.
RX   PubMed=11497239; DOI=10.1007/pl00000910;
RA   Pancholi V.;
RT   "Multifunctional alpha-enolase: its role in diseases.";
RL   Cell. Mol. Life Sci. 58:902-920(2001).
RN   [27]
RP   INTERACTION WITH TRAPPC2B (ISOFORM MBP-1).
RX   PubMed=11134351; DOI=10.1128/mcb.21.2.655-662.2001;
RA   Ghosh A.K., Majumder M., Steele R., White R.A., Ray R.B.;
RT   "A novel 16-kilodalton cellular protein physically interacts with and
RT   antagonizes the functional activity of c-myc promoter-binding protein 1.";
RL   Mol. Cell. Biol. 21:655-662(2001).
RN   [28]
RP   IDENTIFICATION AS AN AUTOANTIGEN IN HASHIMOTO ENCEPHALOPATHY.
RX   PubMed=12297304; DOI=10.1016/s0014-5793(02)03307-0;
RA   Ochi H., Horiuchi I., Araki N., Toda T., Araki T., Sato K., Murai H.,
RA   Osoegawa M., Yamada T., Okamura K., Ogino T., Mizumoto K., Yamashita H.,
RA   Saya H., Kira J.;
RT   "Proteomic analysis of human brain identifies alpha-enolase as a novel
RT   autoantigen in Hashimoto's encephalopathy.";
RL   FEBS Lett. 528:197-202(2002).
RN   [29]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-44 AND TYR-287, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [31]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal
RT   differential cellular gene expression in response to enterovirus 71
RT   infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [32]
RP   ISGYLATION.
RX   PubMed=16815975; DOI=10.1073/pnas.0600397103;
RA   Wong J.J., Pung Y.F., Sze N.S., Chin K.C.;
RT   "HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I
RT   IFN-induced ISGylation of protein targets.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10735-10740(2006).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-254 AND SER-263, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-272, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-5; LYS-64; LYS-71; LYS-89;
RP   LYS-126; LYS-193; LYS-199; LYS-228; LYS-233; LYS-256; LYS-281; LYS-285 AND
RP   LYS-420, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   MALONYLATION AT LYS-233 AND LYS-420.
RX   PubMed=21908771; DOI=10.1074/mcp.m111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y., He W.,
RA   Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C., Dai J.,
RA   Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-254; SER-263 AND
RP   SER-272, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-291, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [43]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-202, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [44]
RP   INTERACTION WITH CMTM6, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=28813417; DOI=10.1038/nature23643;
RA   Burr M.L., Sparbier C.E., Chan Y.C., Williamson J.C., Woods K.,
RA   Beavis P.A., Lam E.Y.N., Henderson M.A., Bell C.C., Stolzenburg S.,
RA   Gilan O., Bloor S., Noori T., Morgens D.W., Bassik M.C., Neeson P.J.,
RA   Behren A., Darcy P.K., Dawson S.J., Voskoboinik I., Trapani J.A., Cebon J.,
RA   Lehner P.J., Dawson M.A.;
RT   "CMTM6 maintains the expression of PD-L1 and regulates anti-tumour
RT   immunity.";
RL   Nature 549:101-105(2017).
RN   [45]
RP   FUNCTION, CATALYTIC ACTIVITY, HYDROXYBUTYRYLATION AT LYS-228 AND LYS-281,
RP   AND MUTAGENESIS OF LYS-281.
RX   PubMed=29775581; DOI=10.1016/j.molcel.2018.04.011;
RA   Huang H., Tang S., Ji M., Tang Z., Shimada M., Liu X., Qi S.,
RA   Locasale J.W., Roeder R.G., Zhao Y., Li X.;
RT   "p300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis.";
RL   Mol. Cell 70:663-678(2018).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2-434, SUBUNIT, COFACTOR, AND
RP   METAL-BINDING SITES.
RX   PubMed=18560153; DOI=10.1107/s0907444908008561;
RA   Kang H.J., Jung S.K., Kim S.J., Chung S.J.;
RT   "Structure of human alpha-enolase (hENO1), a multifunctional glycolytic
RT   enzyme.";
RL   Acta Crystallogr. D 64:651-657(2008).
CC   -!- FUNCTION: Enolase that catalyzes the conversion of 2-phosphoglycerate
CC       to phosphoenolpyruvate in glycolysis and the reverse reaction in
CC       gluconeogenesis (PubMed:1369209, PubMed:29775581). Also involved in
CC       various processes such as growth control, hypoxia tolerance and
CC       allergic responses (PubMed:10802057, PubMed:12666133, PubMed:2005901,
CC       PubMed:29775581). May also function in the intravascular and
CC       pericellular fibrinolytic system due to its ability to serve as a
CC       receptor and activator of plasminogen on the cell surface of several
CC       cell-types such as leukocytes and neurons (PubMed:12666133). Stimulates
CC       immunoglobulin production (PubMed:1369209).
CC       {ECO:0000269|PubMed:10802057, ECO:0000269|PubMed:12666133,
CC       ECO:0000269|PubMed:1369209, ECO:0000269|PubMed:2005901,
CC       ECO:0000269|PubMed:29775581}.
CC   -!- FUNCTION: [Isoform MBP-1]: Binds to the myc promoter and acts as a
CC       transcriptional repressor. May be a tumor suppressor.
CC       {ECO:0000269|PubMed:10082554}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-2-phosphoglycerate = phosphoenolpyruvate + H2O;
CC         Xref=Rhea:RHEA:10164, ChEBI:CHEBI:15377, ChEBI:CHEBI:58289,
CC         ChEBI:CHEBI:58702; EC=4.2.1.11; Evidence={ECO:0000269|PubMed:1369209,
CC         ECO:0000269|PubMed:29775581};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10165;
CC         Evidence={ECO:0000305|PubMed:1369209, ECO:0000305|PubMed:29775581};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:10166;
CC         Evidence={ECO:0000305};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:18560153};
CC       Note=Binds two Mg(2+) per subunit. Required for catalysis and for
CC       stabilizing the dimer. {ECO:0000269|PubMed:18560153};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Enolase activity is lost above pH 9.0. Immunoglobulin production
CC         stimulating activity is retained at pH 13.0.
CC         {ECO:0000269|PubMed:1369209};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 4/5. {ECO:0000305|PubMed:1369209}.
CC   -!- SUBUNIT: Mammalian enolase is composed of 3 isozyme subunits, alpha,
CC       beta and gamma, which can form homodimers or heterodimers which are
CC       cell-type and development-specific (PubMed:18560153). ENO1 interacts
CC       with PLG in the neuronal plasma membrane and promotes its activation.
CC       The C-terminal lysine is required for this binding (PubMed:9308760).
CC       Isoform MBP-1 interacts with TRAPPC2B (PubMed:11134351). Interacts with
CC       ENO4 and PGAM2 (By similarity). Interacts with CMTM6 (PubMed:28813417).
CC       {ECO:0000250|UniProtKB:P17182, ECO:0000269|PubMed:11134351,
CC       ECO:0000269|PubMed:18560153, ECO:0000269|PubMed:28813417,
CC       ECO:0000269|PubMed:9308760}.
CC   -!- INTERACTION:
CC       P06733; P22303: ACHE; NbExp=2; IntAct=EBI-353877, EBI-1637793;
CC       P06733; P09104: ENO2; NbExp=5; IntAct=EBI-353877, EBI-713154;
CC       P06733; P13929: ENO3; NbExp=3; IntAct=EBI-353877, EBI-4287222;
CC       P06733; P42858: HTT; NbExp=13; IntAct=EBI-353877, EBI-466029;
CC       P06733; P12004: PCNA; NbExp=3; IntAct=EBI-353877, EBI-358311;
CC       P06733; Q8WZ42: TTN; NbExp=3; IntAct=EBI-353877, EBI-681210;
CC       P06733; P63104: YWHAZ; NbExp=3; IntAct=EBI-353877, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10802057}. Cell
CC       membrane {ECO:0000269|PubMed:10802057}. Cytoplasm, myofibril,
CC       sarcomere, M line {ECO:0000269|PubMed:10802057}. Note=Can translocate
CC       to the plasma membrane in either the homodimeric (alpha/alpha) or
CC       heterodimeric (alpha/gamma) form. ENO1 is localized to the M line.
CC   -!- SUBCELLULAR LOCATION: [Isoform MBP-1]: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=alpha-enolase;
CC         IsoId=P06733-1; Sequence=Displayed;
CC       Name=MBP-1;
CC         IsoId=P06733-2; Sequence=VSP_018725;
CC   -!- TISSUE SPECIFICITY: The alpha/alpha homodimer is expressed in embryo
CC       and in most adult tissues. The alpha/beta heterodimer and the beta/beta
CC       homodimer are found in striated muscle, and the alpha/gamma heterodimer
CC       and the gamma/gamma homodimer in neurons.
CC   -!- DEVELOPMENTAL STAGE: During ontogenesis, there is a transition from the
CC       alpha/alpha homodimer to the alpha/beta heterodimer in striated muscle
CC       cells, and to the alpha/gamma heterodimer in nerve cells.
CC   -!- INDUCTION: Induced in diffuse large cell lymphoma (DLCL) after
CC       treatment with the natural biological agent, Bryo1. Up-regulated in
CC       response to enterovirus 71 (EV71) infection (at protein level).
CC       {ECO:0000269|PubMed:16548883, ECO:0000269|PubMed:7787969}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798,
CC       ECO:0000269|PubMed:16815975}.
CC   -!- PTM: Lysine 2-hydroxyisobutyrylation (Khib) by p300/EP300 activates the
CC       phosphopyruvate hydratase activity. {ECO:0000269|PubMed:29775581}.
CC   -!- MISCELLANEOUS: Used as a diagnostic marker for many tumors and, in the
CC       heterodimeric form, alpha/gamma, as a marker for hypoxic brain injury
CC       after cardiac arrest. Also marker for endometriosis. Antibodies against
CC       alpha-enolase are present in sera from patients with cancer-associated
CC       retinopathy syndrome (CAR), a progressive blinding disease which occurs
CC       in the presence of systemic tumor growth, primarily small-cell
CC       carcinoma of the lung and other malignancies. Is identified as an
CC       autoantigen in Hashimoto encephalopathy (HE) a rare autoimmune disease
CC       associated with Hashimoto thyroiditis (HT). HT is a disorder in which
CC       destructive processes overcome the potential capacity of thyroid
CC       replacement leading to hypothyroidism.
CC   -!- MISCELLANEOUS: [Isoform MBP-1]: It is uncertain whether the alternative
CC       initiation site is at Met-94 or at Met-97. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the enolase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35698.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA35698.1; Type=Miscellaneous discrepancy; Note=Sequencing errors.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40453/ENO1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M14328; AAA52387.1; -; mRNA.
DR   EMBL; X16288; CAA34360.1; -; Genomic_DNA.
DR   EMBL; X16289; CAA34360.1; JOINED; Genomic_DNA.
DR   EMBL; X16290; CAA34360.1; JOINED; Genomic_DNA.
DR   EMBL; M55914; AAA35698.1; ALT_FRAME; mRNA.
DR   EMBL; X84907; CAA59331.1; -; mRNA.
DR   EMBL; BT007163; AAP35827.1; -; mRNA.
DR   EMBL; AK315417; BAG37806.1; -; mRNA.
DR   EMBL; AL833741; CAH56247.1; -; mRNA.
DR   EMBL; BX537400; CAD97642.1; -; mRNA.
DR   EMBL; AK222517; BAD96237.1; -; mRNA.
DR   EMBL; AK223192; BAD96912.1; -; mRNA.
DR   EMBL; DQ056744; AAY43128.1; -; Genomic_DNA.
DR   EMBL; AL139415; CAC42425.1; -; Genomic_DNA.
DR   EMBL; CH471130; EAW71604.1; -; Genomic_DNA.
DR   EMBL; BC001810; AAH01810.1; -; mRNA.
DR   EMBL; BC004325; AAH04325.1; -; mRNA.
DR   EMBL; BC004458; AAH04458.1; -; mRNA.
DR   EMBL; BC009218; AAH09218.2; -; mRNA.
DR   EMBL; BC009912; AAH09912.1; -; mRNA.
DR   EMBL; BC011130; AAH11130.1; -; mRNA.
DR   EMBL; BC015641; AAH15641.1; -; mRNA.
DR   EMBL; BC021166; AAH21166.2; -; mRNA.
DR   EMBL; BC022545; AAH22545.1; -; mRNA.
DR   EMBL; BC027725; AAH27725.1; -; mRNA.
DR   EMBL; BC050642; AAH50642.1; -; mRNA.
DR   EMBL; U88968; AAC39935.1; -; mRNA.
DR   EMBL; AF035286; AAB88178.1; -; mRNA.
DR   CCDS; CCDS97.1; -. [P06733-1]
DR   PIR; A39579; A39579.
DR   PIR; S11696; A29170.
DR   RefSeq; NP_001188412.1; NM_001201483.4. [P06733-2]
DR   RefSeq; NP_001419.1; NM_001428.5. [P06733-1]
DR   PDB; 2PSN; X-ray; 2.20 A; A/B/C/D=1-434.
DR   PDB; 3B97; X-ray; 2.20 A; A/B/C/D=2-434.
DR   PDB; 5JLZ; X-ray; 1.99 A; E/F=26-40.
DR   PDB; 5LAX; X-ray; 2.60 A; E/F=26-40.
DR   PDB; 5NI9; X-ray; 1.33 A; C=326-340.
DR   PDB; 5NIG; X-ray; 1.35 A; C=326-340.
DR   PDB; 5OCK; X-ray; 1.60 A; A=5-21.
DR   PDB; 8TRL; X-ray; 2.40 A; C/F=10-22.
DR   PDBsum; 2PSN; -.
DR   PDBsum; 3B97; -.
DR   PDBsum; 5JLZ; -.
DR   PDBsum; 5LAX; -.
DR   PDBsum; 5NI9; -.
DR   PDBsum; 5NIG; -.
DR   PDBsum; 5OCK; -.
DR   PDBsum; 8TRL; -.
DR   AlphaFoldDB; P06733; -.
DR   SMR; P06733; -.
DR   BioGRID; 108338; 744.
DR   FunCoup; P06733; 1402.
DR   IntAct; P06733; 164.
DR   MINT; P06733; -.
DR   STRING; 9606.ENSP00000495530; -.
DR   BindingDB; P06733; -.
DR   ChEMBL; CHEMBL3298; -.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   MoonDB; P06733; Predicted.
DR   MoonProt; P06733; -.
DR   GlyCosmos; P06733; 1 site, 1 glycan.
DR   GlyGen; P06733; 4 sites, 4 N-linked glycans (2 sites), 2 O-linked glycans (2 sites).
DR   iPTMnet; P06733; -.
DR   MetOSite; P06733; -.
DR   PhosphoSitePlus; P06733; -.
DR   SwissPalm; P06733; -.
DR   BioMuta; ENO1; -.
DR   DMDM; 119339; -.
DR   OGP; P06733; -.
DR   REPRODUCTION-2DPAGE; IPI00465248; -.
DR   REPRODUCTION-2DPAGE; P06733; -.
DR   CPTAC; CPTAC-70; -.
DR   jPOST; P06733; -.
DR   MassIVE; P06733; -.
DR   PaxDb; 9606-ENSP00000234590; -.
DR   PeptideAtlas; P06733; -.
DR   PRIDE; P06733; -.
DR   ProteomicsDB; 51919; -. [P06733-1]
DR   ProteomicsDB; 51920; -. [P06733-2]
DR   Pumba; P06733; -.
DR   TopDownProteomics; P06733-1; -. [P06733-1]
DR   TopDownProteomics; P06733-2; -. [P06733-2]
DR   ABCD; P06733; 5 sequenced antibodies.
DR   Antibodypedia; 4351; 880 antibodies from 45 providers.
DR   DNASU; 2023; -.
DR   Ensembl; ENST00000234590.10; ENSP00000234590.4; ENSG00000074800.17. [P06733-1]
DR   GeneID; 2023; -.
DR   KEGG; hsa:2023; -.
DR   MANE-Select; ENST00000234590.10; ENSP00000234590.4; NM_001428.5; NP_001419.1.
DR   UCSC; uc001apj.3; human. [P06733-1]
DR   AGR; HGNC:3350; -.
DR   ClinPGx; PA27786; -.
DR   CTD; 2023; -.
DR   DisGeNET; 2023; -.
DR   GeneCards; ENO1; -.
DR   HGNC; HGNC:3350; ENO1.
DR   HPA; ENSG00000074800; Low tissue specificity.
DR   MalaCards; ENO1; -.
DR   MIM; 172430; gene.
DR   OpenTargets; ENSG00000074800; -.
DR   VEuPathDB; HostDB:ENSG00000074800; -.
DR   eggNOG; KOG2670; Eukaryota.
DR   GeneTree; ENSGT00950000182805; -.
DR   HOGENOM; CLU_031223_0_0_1; -.
DR   InParanoid; P06733; -.
DR   OMA; RCMMSHR; -.
DR   OrthoDB; 1739814at2759; -.
DR   PAN-GO; P06733; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; P06733; -.
DR   BioCyc; MetaCyc:ENSG00000074800-MONOMER; -.
DR   BRENDA; 4.2.1.11; 2681.
DR   PathwayCommons; P06733; -.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   Reactome; R-HSA-9636667; Manipulation of host energy metabolism.
DR   SABIO-RK; P06733; -.
DR   SignaLink; P06733; -.
DR   SIGNOR; P06733; -.
DR   UniPathway; UPA00109; UER00187.
DR   Agora; ENSG00000074800; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 2023; 463 hits in 1178 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; ENO1; human.
DR   EvolutionaryTrace; P06733; -.
DR   GeneWiki; Alpha-enolase; -.
DR   GenomeRNAi; 2023; -.
DR   Pharos; P06733; Tchem.
DR   PRO; PR:P06733; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P06733; protein.
DR   Bgee; ENSG00000074800; Expressed in metanephros cortex and 220 other cell types or tissues.
DR   ExpressionAtlas; P06733; baseline and differential.
DR   GO; GO:0005938; C:cell cortex; IDA:CAFA.
DR   GO; GO:0009986; C:cell surface; IDA:CAFA.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0031430; C:M band; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:CAFA.
DR   GO; GO:0005640; C:nuclear outer membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0000015; C:phosphopyruvate hydratase complex; IDA:CAFA.
DR   GO; GO:0005886; C:plasma membrane; IDA:CAFA.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004634; F:phosphopyruvate hydratase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB.
DR   GO; GO:0061621; P:canonical glycolysis; IDA:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IBA:GO_Central.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:1903298; P:negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway; IDA:CAFA.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:CAFA.
DR   GO; GO:2001171; P:positive regulation of ATP biosynthetic process; IDA:CAFA.
DR   GO; GO:0045933; P:positive regulation of muscle contraction; IGI:CAFA.
DR   GO; GO:0010756; P:positive regulation of plasminogen activation; IMP:CAFA.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   CDD; cd03313; enolase; 1.
DR   FunFam; 3.30.390.10:FF:000001; Enolase; 1.
DR   FunFam; 3.20.20.120:FF:000002; Enolase 1; 1.
DR   Gene3D; 3.20.20.120; Enolase-like C-terminal domain; 1.
DR   Gene3D; 3.30.390.10; Enolase-like, N-terminal domain; 1.
DR   HAMAP; MF_00318; Enolase; 1.
DR   InterPro; IPR000941; Enolase.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR020810; Enolase_C.
DR   InterPro; IPR020809; Enolase_CS.
DR   InterPro; IPR020811; Enolase_N.
DR   NCBIfam; TIGR01060; eno; 1.
DR   PANTHER; PTHR11902:SF12; ALPHA-ENOLASE; 1.
DR   PANTHER; PTHR11902; ENOLASE; 1.
DR   Pfam; PF00113; Enolase_C; 1.
DR   Pfam; PF03952; Enolase_N; 1.
DR   PIRSF; PIRSF001400; Enolase; 1.
DR   PRINTS; PR00148; ENOLASE.
DR   SFLD; SFLDS00001; Enolase; 1.
DR   SFLD; SFLDF00002; enolase; 1.
DR   SFLD; SFLDG00178; enolase; 1.
DR   SMART; SM01192; Enolase_C; 1.
DR   SMART; SM01193; Enolase_N; 1.
DR   SUPFAM; SSF51604; Enolase C-terminal domain-like; 1.
DR   SUPFAM; SSF54826; Enolase N-terminal domain-like; 1.
DR   PROSITE; PS00164; ENOLASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Cell membrane;
KW   Cytoplasm; Direct protein sequencing; DNA-binding; Glycolysis;
KW   Hydroxylation; Isopeptide bond; Lyase; Magnesium; Membrane; Metal-binding;
KW   Nucleus; Phosphoprotein; Plasminogen activation; Proteomics identification;
KW   Reference proteome; Repressor; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.14, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..434
FT                   /note="Alpha-enolase"
FT                   /id="PRO_0000134097"
FT   REGION          31..38
FT                   /note="Epitope recognized by CAR and healthy patient
FT                   antibodies"
FT   REGION          56..63
FT                   /note="Epitope recognized by CAR antibodies"
FT   REGION          97..237
FT                   /note="Required for repression of c-myc promoter activity"
FT   REGION          405..434
FT                   /note="Required for interaction with PLG"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        210
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   ACT_SITE        343
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   BINDING         40
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:18560153"
FT   BINDING         158
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   BINDING         167
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   BINDING         245
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:18560153"
FT   BINDING         293
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:18560153"
FT   BINDING         293
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   BINDING         318
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:18560153"
FT   BINDING         318
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   BINDING         370..373
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   BINDING         394
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00924"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.14, ECO:0007744|PubMed:25944712"
FT   MOD_RES         5
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         44
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         60
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         60
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         64
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         71
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         89
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         89
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         92
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         126
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         193
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         199
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         202
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         228
FT                   /note="N6-(2-hydroxyisobutyryl)lysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:29775581"
FT   MOD_RES         228
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         228
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         233
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         233
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         256
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         272
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         281
FT                   /note="N6-(2-hydroxyisobutyryl)lysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:29775581"
FT   MOD_RES         281
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         285
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         287
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         291
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         335
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         343
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         406
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   MOD_RES         420
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         420
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         420
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17182"
FT   CROSSLNK        202
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..93
FT                   /note="Missing (in isoform MBP-1)"
FT                   /evidence="ECO:0000303|PubMed:2005901"
FT                   /id="VSP_018725"
FT   VARIANT         177
FT                   /note="N -> K (in dbSNP:rs11544513)"
FT                   /evidence="ECO:0000269|Ref.9"
FT                   /id="VAR_025172"
FT   VARIANT         325
FT                   /note="P -> Q (in dbSNP:rs11544514)"
FT                   /id="VAR_048936"
FT   MUTAGEN         94
FT                   /note="M->I: MBP1 protein production. No MBP1 protein
FT                   production; when associated with I-97."
FT                   /evidence="ECO:0000269|PubMed:10681589"
FT   MUTAGEN         97
FT                   /note="M->I: MBP1 protein production. No MBP1 protein
FT                   production; when associated with I-94."
FT                   /evidence="ECO:0000269|PubMed:10681589"
FT   MUTAGEN         281
FT                   /note="K->R: Decreased 2-hydroxyisobutyrylation leading to
FT                   decreased phosphopyruvate hydratase activity."
FT                   /evidence="ECO:0000269|PubMed:29775581"
FT   MUTAGEN         384
FT                   /note="L->A: Loss of transcriptional repression and cell
FT                   growth inhibition; when associated with A-388."
FT                   /evidence="ECO:0000269|PubMed:10082554"
FT   MUTAGEN         388
FT                   /note="L->A: Loss of transcriptional repression and cell
FT                   growth inhibition; when associated with A-384."
FT                   /evidence="ECO:0000269|PubMed:10082554"
FT   CONFLICT        55
FT                   /note="T -> A (in Ref. 8; CAD97642)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        78
FT                   /note="V -> A (in Ref. 7; BAD96237)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        187
FT                   /note="E -> G (in Ref. 8; CAD97642)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        199
FT                   /note="K -> R (in Ref. 7; BAD96912)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        252
FT                   /note="F -> S (in Ref. 4; CAA59331)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        310
FT                   /note="S -> I (in Ref. 8; CAD97642)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..12
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          18..26
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          29..34
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           63..71
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           73..79
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           87..98
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   TURN            104..106
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           108..125
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           130..138
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          147..154
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           156..158
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          159..162
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          167..171
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           178..200
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           202..204
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           220..233
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   TURN            237..239
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          241..245
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           248..250
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   TURN            259..262
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           267..269
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           273..286
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          289..293
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           301..311
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          313..318
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   TURN            319..323
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           325..334
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          338..342
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           344..347
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           350..362
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          366..370
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           380..387
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   STRAND          391..394
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           401..417
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           418..420
FT                   /evidence="ECO:0007829|PDB:2PSN"
FT   HELIX           425..427
FT                   /evidence="ECO:0007829|PDB:2PSN"
SQ   SEQUENCE   434 AA;  47169 MW;  A0ED663FCC15ADA5 CRC64;
     MSILKIHARE IFDSRGNPTV EVDLFTSKGL FRAAVPSGAS TGIYEALELR DNDKTRYMGK
     GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT ENKSKFGANA ILGVSLAVCK
     AGAVEKGVPL YRHIADLAGN SEVILPVPAF NVINGGSHAG NKLAMQEFMI LPVGAANFRE
     AMRIGAEVYH NLKNVIKEKY GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV
     VIGMDVAASE FFRSGKYDLD FKSPDDPSRY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD
     WGAWQKFTAS AGIQVVGDDL TVTNPKRIAK AVNEKSCNCL LLKVNQIGSV TESLQACKLA
     QANGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR SERLAKYNQL LRIEEELGSK
     AKFAGRNFRN PLAK
//
